MindWalk publishes Discovery-to-Clinic presentation factsheet

• MindWalk Holdings published a Discovery-to-Clinic presentation detailing more than 20 partner-owned drug candidates originating from its antibody discovery work, including 10 programs in active Phase 1-3 clinical trials.
• Highlighted clinical-stage assets include Annexon’s ANX005 in Phase 3 for Guillain-Barré Syndrome, argenx’s ARGX-119 in Phase 2/3 for Congenital Myasthenic Syndrome, Xencor’s vudalimab/XmAb20717 in Phase 1-2 for solid tumors.
• The factsheet also outlines the HYFT biological intelligence infrastructure, including a knowledge graph indexing 660 million biological patterns and 25 billion relationships.
• Document link: https://s201.q4cdn.com/648240662/files/doc_presentations/2026/May/18/MindWalk_Discovery_to_Clinic_v9.pdf.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.